FindTrial
Sign In

Oral repotrectinib (TPX-0005)

DRUG2 trials

Sponsors

Turning Point Therapeutics, Inc.

Conditions

Locally Advanced Solid TumorsLymphomaMetastatic Solid TumorsPrimary CNS Tumors

Phase 1

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
RecruitingNCT03093116
Turning Point Therapeutics, Inc.Locally Advanced Solid Tumors, Metastatic Solid Tumors
Start: 2017-03-07End: 2028-02-29Target: 500Updated: 2026-05-27
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingNCT04094610
Turning Point Therapeutics, Inc.Locally Advanced Solid Tumors, Lymphoma, Metastatic Solid Tumors +1
Start: 2020-03-12End: 2027-09-30Target: 75Updated: 2026-09-04

Related Papers

Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial
Nature Medicine2026-02-04
FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer
Clinical Cancer Research2024-06-1410 citations
Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced <i>ROS1</i> fusion-positive (<i>ROS1+)</i> NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies.
Journal of Clinical Oncology2024-06-011 citations
Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer
New England Journal of Medicine2024-01-10170 citations
Abstract PR003: Repotrectinib in patients with <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC): Update from the pivotal phase 1/2 TRIDENT-1 trial
Molecular Cancer Therapeutics2023-12-012 citations
Intracranial and systemic efficacy of repotrectinib in advanced <i>ROS1</i> fusion-positive (<i>ROS1</i>+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.
Journal of Clinical Oncology2023-06-0113 citations
Abstract P02-01: Repotrectinib in patients with <i>NTRK</i> fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial
Molecular Cancer Therapeutics2021-12-017 citations
Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with <i>ROS1</i>+ advanced non-small cell lung cancer and with <i>NTRK</i>+ advanced solid tumors (TRIDENT-1)
Molecular Cancer Therapeutics2021-12-013 citations
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Molecular Cancer Therapeutics2021-10-0472 citations
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring <i>ROS1</i> or <i>NTRK1-3</i> rearrangements.
Journal of Clinical Oncology2020-05-2012 citations
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer
Clinical Cancer Research2020-04-13115 citations
Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
Cancer Research2019-07-0128 citations
Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
Clinical Research (Excluding Clinical Trials)2019-07-018 citations
Abstract 1319: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations
Cancer Research2019-07-011 citations
Abstract 3071: Repotrectinib demonstrates promising activities in <i>ROS1</i> wild-type and solvent-front mutant lung cancer patients-derived preclinical models
Cancer Research2019-07-01
Abstract 3071: Repotrectinib demonstrates promising activities in<i>ROS1</i>wild-type and solvent-front mutant lung cancer patients-derived preclinical models
Experimental and Molecular Therapeutics2019-07-01
Abstract 1319: Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations
Experimental and Molecular Therapeutics2019-07-01
Safety and preliminary clinical activity of repotrectinib in patients with advanced <i>ROS1</i> fusion-positive non-small cell lung cancer (TRIDENT-1 study).
Journal of Clinical Oncology2019-05-2071 citations
Abstract 4796: Ropotrectinib is a novel polypharmacology kinase inhibitor against WT and mutant ROS1, TRK and ALK
Cancer Research2018-07-01
A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced <i>ALK/ROS1/NTRK+</i> cancers (TRIDENT-1).
Journal of Clinical Oncology2018-05-2018 citations

3 more papers not shown